Clinical Trial Update: Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating ofatumumab as initial systemic therapy for indolent B-cell lymphomas has completed, with results posted in March 2017. The trial enco…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Ofatumumab (ofatumumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-03-17